English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
EndNote (UTF-8)
 
DownloadE-Mail
  ALPK2 prevents cardiac diastolic dysfunction in heart failure with preserved ejection fraction

Yoshida, T., Yoshida, S., Inukai, K., Kato, K., Yura, Y., Hattori, T., et al. (2024). ALPK2 prevents cardiac diastolic dysfunction in heart failure with preserved ejection fraction. FASEB JOURNAL, 38(22): e70192. doi:10.1096/fj.202402103R.

Item is

Files

show Files

Locators

show

Creators

hide
 Creators:
Yoshida, Tatsuya, Author
Yoshida, Satoya, Author
Inukai, Kohei, Author
Kato, Katsuhiro, Author
Yura, Yoshimitsu, Author
Hattori, Tomoki, Author
Taki, Kentaro, Author
Enomoto, Atsushi, Author
Ohashi, Koji, Author
Okumura, Takahiro, Author
Ouchi, Noriyuki, Author
Kawase, Haruya, Author
Wettschureck, Nina1, Author           
Offermanns, Stefan1, Author           
Murohara, Toyoaki, Author
Takefuji, Mikito1, Author           
Affiliations:
1Pharmacology, Max Planck Institute for Heart and Lung Research, Max Planck Society, ou_2591696              

Content

hide
Free keywords: -
 Abstract: Protein phosphorylation, controlled by protein kinases, is central to regulating various pathophysiological processes, including cardiac systolic function. The dysregulation of protein kinase activity plays a significant role in the pathogenesis of cardiac systolic dysfunction. While cardiac contraction mechanisms are well documented, the mechanisms underlying cardiac diastole remain elusive. This gap persists owing to the historical focus on systolic dysfunction in heart failure research. Recently, heart failure with preserved ejection fraction (HFpEF), an age-related disease characterized by cardiac diastolic dysfunction, has emerged as a major public health concern. However, its underlying mechanism remains unclear. In this study, we investigated cardiac protein kinases by analyzing the gene expression of 518 protein kinases in human tissues. We identified alpha-kinase 2 (ALPK2) as a novel cardiac-specific atypical kinase and generated tamoxifen-inducible, cardiomyocyte-specific Alpk2-knockout mice and Alpk2-overexpressing mice. Alpk2 deficiency did not affect cardiac systolic dysfunction in the myocardial infarction model or the pressure-overload-induced heart failure model. Notably, cardiomyocyte-specific Alpk2 deficiency exacerbated cardiac diastolic dysfunction induced by aging and in the HFpEF model. Conversely, Alpk2 overexpression increased the phosphorylation of tropomyosin 1, a major regulator that binds myosin to actin, and mitigated cardiac stiffness in HFpEF. This study provides novel evidence that ALPK2 represents a potential therapeutic target for cardiac diastolic dysfunction in HFpEF and age-related cardiac impairments.

Details

hide
Language(s):
 Dates: 2024-11-302024-11-30
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: ISI: 001368916400001
DOI: 10.1096/fj.202402103R
PMID: 39556326
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

hide
Title: FASEB JOURNAL
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 38 (22) Sequence Number: e70192 Start / End Page: - Identifier: ISSN: 0892-6638